Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | RORC | P51449 | 5/20 | 0.38 |
| ▸ | RARG | P13631 | 1/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.36 |
| ▸ | KDM5A | P29375 | 2/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.36 |
| ▸ | IGF1R | P08069 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | TDO2 | P48775 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9895366 | 0.91 | MAP4K4 (0.37) | EGLN1MAP4K4CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9894706 | 0.90 | MAPT (0.45) | EGLN1IGF1RKMT2ADHODHIDO1 | |
| SCHEMBL9895060 | 0.89 | KDM5A (0.36) | EGLN1KDM4CKDM5AKDM5BDHODH | |
| SCHEMBL9894972 | 0.87 | CYP1A2 (0.36) | EGLN1KMT2ALMNACYP1A2CYP3A4 | |
| SCHEMBL21402167 | 0.83 | KMT2A (0.38) | EGLN1KMT2ADHODH | |
| SCHEMBL27933840 | 0.80 | KDM4C (0.42) | MAP4K4KDM4CKDM5AKDM5BKMT2A | |
| SCHEMBL9895921 | 0.80 | HTR5A (0.36) | MAP4K4 | |
| SCHEMBL9895403 | 0.79 | RAB9A (0.45) | KMT2ADHODHLMNAIDO1TDO2 | |
| SCHEMBL9895430 | 0.77 | GABRA5 (0.44) | EGLN1 | |
| SCHEMBL9894802 | 0.75 | MAPK14 (0.43) | CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | claimed |
| EP-2649064-B1 | NOVEL TRIAZOLE COMPOUNDS III | HOFFMANN LA ROCHE (CH) | 2019-10-02 | — | — | EP | disclosed |
| EP-2649064-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. Hoffmann-La Roche AG (CH) | 2013-10-16 | — | — | EP | disclosed |
| US-8466181-B2 | 1,2,3-triazole-imidazole compounds | HOFFMANN-LA ROCHE INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | HOFFMANN-LA ROCHE INC. | 2012-06-14 | — | — | US | disclosed |
| WO-2012076590-A1 | NOVEL TRIAZOLE COMPOUNDS III | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149675-A1 | 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS | GABRA5, GABRA1, GABRB1 | EGLN1 2395/4885RORC 350/4885RARG 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.